Author:
Kang Dong-Won,Wang Li,Short Nicholas J.,Ferrajoli Alessandra,Wang Yucai,Zhou Shouhao,Shen Chan
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference42 articles.
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.
2. Moreno C. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematol Am Soc Hematol Educ Program. 2020;2020(1):33–40. https://doi.org/10.1182/hematology.2020000086.
3. Woyach JA. Management of relapsed/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97(Suppl. 2):S11–8. https://doi.org/10.1002/ajh.26683.
4. Raedler LA. Imbruvica (ibrutinib), first-in-class Bruton’s tyrosine kinase inhibitor, receives expanded indications for patients with relapsed chronic lymphocytic leukemia. Am Health Drug Benefits. 2015;8(Spec Future):66–9.
5. Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–63. https://doi.org/10.1002/ajh.25638.